News
Market and company headlines
ARMPAll
Loading
07:00-09:00Sep 232 Stories
Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program
Armata Pharmaceuticals technical headwinds overshadow a $3.7 million Department of Defense grant funding its Phase 3 bacteriophage program.
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $3.7 million in non-dilutive funds from the U.S. Department of War ("DoW") to support activities associated with the Phase 3 development p
03:00-07:00Sep 232 Stories
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $15 price target.
Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02
Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium
07:00Sep 211 Story
13:00-18:00Sep 142 Stories
What's going on in today's after hours session
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Circle8 Group (NASDAQ:CIRC) stock moved upwards by 14.6% to $0.57 during Monday's after-market session. The company's market cap stands at $50.2 million. Eocene (NASDAQ:EOCN) shares rose 10.65% to
07:00-10:00Sep 142 Stories
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
Armata Pharmaceuticals (AMEX:ARMP) shares rose 8% after the company said the US Food and Drug Administration granted Breakthrough Therapy designation to AP-SA02, its intravenously administered Staphylococcus aureus multi-phage product candidate. The designation covers AP-SA02 as an adjunct treatment for complicated bacteremia caused by methicillin-sensitive S.
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Therapy designation to AP-SA02, the Company's intravenously administered Staphylococcus aureu
03:00-05:00Sep 142 Stories
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 44.6% to $2.4 during Monday's pre-market session. The company's market cap stands at $1.1 million. Definium Therapeutics (NASDAQ:DFTX)
Armata Pharmaceuticals Receives FDA Breakthrough Therapy Designation For Its Intravenously Administered Staphylococcus Aureus Multi-Phage Product Candidate AP-SA02
Designation for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). Breakthrough Therapy designation is intended to
10:00Aug 131 Story
12:00-17:00Aug 122 Stories
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2026, and provided a corporate update.
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.45) by 38.64 percent. This is a 40 percent increase over losses of $(0.45) per share